Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952908 | 0.87 | PTGDR2 (0.51) | PTGDR2CYP2C9PTGS1SLC6A4CYP2C19 | |
| SCHEMBL2953572 | 0.86 | KIF11 (0.43) | PTGDR2TGFBR1EIF2AK2GSK3BCDK5 | |
| SCHEMBL317661 | 0.85 | PTGDR2 (0.54) | PTGDR2CYP2C9PTGS1SLC6A4CYP2C19 | |
| SCHEMBL317189 | 0.85 | PTGDR2 (0.53) | PTGDR2CYP2C9PTGS1SLC6A4CYP2C19 | |
| SCHEMBL2955003 | 0.80 | MAPK14 (0.47) | PTGDR2CYP2C9PTGS1SLC6A4CYP2C19 | |
| SCHEMBL317790 | 0.79 | ACHE (0.40) | PTGDR2CYP2C9PTGS1SLC6A4CYP2C19 | |
| SCHEMBL2961347 | 0.78 | PTGDR2 (0.44) | PTGDR2EIF2AK2CDK5CDK5R1MAPK14 | |
| Hydrochloric Acid SCHEMBL2952627 | 0.78 | CYP2C9 (0.39) | PTGDR2CYP2C9PTGS1SLC6A4CYP2C19 | |
| SCHEMBL3042442 | 0.78 | HTR1A (0.42) | PTGDR2PTGS1BCHEFLT3GSK3A | |
| SCHEMBL317503 | 0.78 | KIF11 (0.46) | PTGDR2PTGS1PTGS2BCHEEIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093278-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20100210685-A1 | Novel Substituted Indoles | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7754735-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210685-A1 | Novel Substituted Indoles | IDO1, IDO2, TPH1 | PTGDR2 429/4885CYP2C9 378/4885PTGS1 413/4885 |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | PTGDR2 54/4885CYP2C9 3502/4885PTGS1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.